Results 21 to 30 of about 11,937 (148)
Montelukast and Coronavirus Disease 2019: A Scoping Review
Iranian Journal of Allergy, Asthma and Immunology, 2021 Coronavirus disease 2019 (COVID-19) is an emerging worldwide issue, that has affected a large number of people around the world. So far, many studies have aimed to develop a therapeutic approach against COVID-19.
Niusha Sharifinejad +4 more
doaj +1 more source
Introduction of Leukotriene Receptor Antagonists in Manitoba
Canadian Respiratory Journal, 2006 Patient characteristics and prescribing patterns during the introduction of leukotriene receptor antagonists (LTRA) in Manitoba are described using the provincial health database.
C Macie +3 more
doaj +1 more source
Biomédica: revista del Instituto Nacional de Salud, 2013 Introducción. Aproximadamente el 50 % de los casos de urticaria crónica no mejoran adecuadamente con las dosis convencionales de antihistamínicos, por lo cual se han planteado múltiples opciones terapéuticas, entre las cuales el omalizumab es una ...
Libia Susana Diez +2 more
doaj +1 more source
Педиатрическая фармакология, 2009 The article provides data regarding the clinical efficacy and safety of leukotriene receptor antagonists in treatment of bronchial asthma in children. The only representative of this group that is allowed in Russia for treatment of children over 6 years ...
Yu.G. Levina, L.S. Namazova-Baranova
doaj +2 more sources
Effect of a Single Dose Montelukast Sodium on Methacholine Chloride PC20
Canadian Respiratory Journal, 2005 BACKGROUND: It is currently recommended that leukotriene modifiers (receptor antagonists and synthesis inhibitors) be withheld for a minimum of 24 h before direct bronchoprovocation testing, but there is little evidence to support this recommendation.
Beth E Davis, Donald W Cockcroft
doaj +1 more source
Journal of Occupational Medicine and Toxicology, 2008 Background Platelet activating factor and tachykinins (substance P, neurokinin A, neurokinin B) are important mediators contributing to increased airway secretion in the context of different types of respiratory diseases including acute and chronic ...
Groneberg David A +3 more
doaj +1 more source
Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors
Nature Communications, 2019 Cysteinyl leukotriene G protein-coupled receptors CysLT1 and CysLT2 regulate pro-inflammatory responses associated with allergic disorders. Here, authors describe four crystal structures of CysLT2R in complex with three dual CysLT1R/CysLT2R antagonists ...
Anastasiia Gusach +23 more
doaj +1 more source
Treatment of refractory chronic urticaria
Indian Journal of Dermatology, 2015 Chronic spontaneous urticaria is a distressing disease encountered frequently in clinical practice. The current mainstay of therapy is the use of second-generation, non-sedating antihistamines.
Aayushi Mehta +4 more
doaj +1 more source
Cross roads between Pulmonology and Psychiatry
Telangana Journal of Psychiatry, 2017 Leukotriene receptor antagonists (Montelukast) has been used for many years in the treatment of asthma in both acute and chronic stages. It is considered safe and is widely used in pediatric age group as well as adults.
M Ajit +2 more
doaj +1 more source
Comparison of Oral Montelukast and Intranasal Fluticasone in Patients with Asthma and Allergic Rhinitis [PDF]
Journal of Clinical and Diagnostic Research, 2016 Introduction: Even though the links between upper and lower airway had been of interest to clinicians since long back, it has not attracted the attention of the researchers till recent past.
Apar Jindal +6 more
doaj +1 more source